Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, Amgen Collaborate on Clinical Trial

NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it will collaborate with Amgen to use its next-generation sequencing-based immune repertoire profiling assay ClonoSeq to measure minimal residual disease in patients with multiple myeloma as part of a phase 3 clinical trial

Amgen is sponsoring the trial and collaborating with Janssen. The trial compares progression-free survival between two drug combinations: Amgen's Kyprolis (carfilzomib), Janssen's Darzalex (daratumumab), and the corticosteroid hormone dexamethasone with a combination just carfilzomib and dexamethasone. Adaptive's ClonoSeq assay will be used to measure MRD status in patients with relapsed or refractory MM.

"Incorporating MRD measurement by the ClonoSeq assay offers Amgen the ability to accurately assess the depth of response generated by Kyprolis treatment in patients with relapsed or refractory MM,” Chad Robins, president, CEO and cofounder of Adaptive Biotechnologies, said in a statement.

The firm has struck previous agreements with both Amgen and Janssen. In June, Adaptive said it would work with Janssen to measure the efficacy of Janssen's Darzalex in MM.

And in January, Adaptive and Amgen said they planned to develop Adaptive's ClonoSeq assay to assess MRD in patients with acute lymphoblastic leukemia.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.